ReviewBiochimica et biophysica acta. General subjects2023
Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development.
Review in Biochimica et biophysica acta. General subjects, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Nanoparticle vaccine formulations for dengue virus.RSC pharmaceutics · 2026Review
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Rationally engineered cationic ferritin nanoparticles overcome pre-existing immunity to adenoviral vectors.Journal of nanobiotechnology · 2026Article
- Identification of efficient multi-epitope combinations against African swine fever virus based on AP205 scaffold-mediated nanodisplay technology.Journal of nanobiotechnology · 2026Article
- Development and Immunogenicity of a Five-Antigen Strangles Vaccine Based on Equine Ferritin Nanoparticles in Mice.Veterinary sciences · 2026Article
- Article
- Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2.NPJ vaccines · 2025Article
- Protein nanocages: A new frontier in mucosal vaccine delivery and immune activation.Human vaccines & immunotherapeutics · 2025Review
- Ferritin Nanocages Exhibit Unique Structural Dynamics When Displaying Surface Protein.International journal of molecular sciences · 2025Article
- Navigating the Complexities of HIV Vaccine Development: Lessons from the Mosaico Trial and Next-Generation Development Strategies.Vaccines · 2025Article
- A Brief History of Ferritin, an Ancient and Versatile Protein.International journal of molecular sciences · 2024Review
- EngineeringVaccines · 2024Review
- The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies.MedComm · 2024Article
- Review
- Article
- Review
- A novel view of ferritin in cancer.Biochimica et biophysica acta. Reviews on cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe development of safe and effective vaccines against SARS-CoV-2 and other viruses with high antigenic drift is of crucial importance to public health. Ferritin is a well characterized and ubiquitous iron storage protein that has emerged not only as a useful nanoreactor and nanocarrier, but more recently as an efficient platform for vaccine development. SCOPE OF REVIEW: This review discusses ferritin structure-function properties, self-assembly, and novel bioengineering strategies such as interior cavity and exterior surface modifications for cargo encapsulation and delivery. It also discusses the use of ferritin as a scaffold for biomedical applications, especially for vaccine development against influenza, Epstein-Barr, HIV, hepatitis-C, Lyme disease, and respiratory viruses such as SARS-CoV-2. The use of ferritin for the synthesis of mosaic vaccines to deliver a cocktail of antigens that elicit broad immune protection against different viral variants is also explored. MAJOR
conclusionsThe remarkable stability, biocompatibility, surface functionalization, and self-assembly properties of ferritin nanoparticles make them very attractive platforms for a wide range of biomedical applications, including the development of vaccines. Strong immune responses have been observed in pre-clinical studies against a wide range of pathogens and have led to the exploration of ferritin nanoparticles-based vaccines in multiple phase I clinical trials. GENERAL SIGNIFICANCE: The broad protective antibody response of ferritin nanoparticles-based vaccines demonstrates the usefulness of ferritin as a highly promising and effective approaches for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.